Astellas Pharma Inc. ADR logo

Astellas Pharma Inc. ADR (ALPMY)

Market Closed
15 Oct, 08:00 PM
OTC PINK OTC PINK
$
14. 98
+0.63
+4.3902%
$
25.73B Market Cap
- P/E Ratio
0.88% Div Yield
27,004 Volume
- Eps
$ 14.35
Previous Close
Add Transaction
Day Range
14.93 15.03
Year Range
10.05 17.35
Want to track ALPMY and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?

Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?

Here is how Astellas Pharma Inc. (ALPMY) and Cardinal Health (CAH) have performed compared to their sector so far this year.

Zacks | 6 months ago
Astellas collaborates with Vir to develop its experimental prostate cancer drug

Astellas collaborates with Vir to develop its experimental prostate cancer drug

Japan's Astellas and Vir Biotechnology said on Monday they will together develop and commercialize the U.S. drug developer's prostate cancer experimental drug.

Reuters | 7 months ago
Astellas Pharma Inc. (ALPMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Astellas Pharma Inc. (ALPMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Astellas Pharma Inc. (ALPMY) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seekingalpha | 9 months ago
Is Alpha Cognition Inc. (ACOG) Outperforming Other Medical Stocks This Year?

Is Alpha Cognition Inc. (ACOG) Outperforming Other Medical Stocks This Year?

Here is how Alpha Cognition Inc. (ACOG) and Astellas Pharma Inc. (ALPMY) have performed compared to their sector so far this year.

Zacks | 1 year ago
Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?

Are Medical Stocks Lagging Astellas Pharma (ALPMY) This Year?

Here is how Astellas Pharma Inc. (ALPMY) and AtriCure (ATRC) have performed compared to their sector so far this year.

Zacks | 1 year ago
Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?

Is Astellas Pharma (ALPMY) Stock Outpacing Its Medical Peers This Year?

Here is how Astellas Pharma Inc. (ALPMY) and AtriCure (ATRC) have performed compared to their sector so far this year.

Zacks | 1 year ago
Here's Why Astellas Pharma (ALPMY) Is a Great 'Buy the Bottom' Stock Now

Here's Why Astellas Pharma (ALPMY) Is a Great 'Buy the Bottom' Stock Now

Astellas Pharma (ALPMY) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Zacks | 1 year ago
Astellas Pharma (ALPMY) Upgraded to Strong Buy: What Does It Mean for the Stock?

Astellas Pharma (ALPMY) Upgraded to Strong Buy: What Does It Mean for the Stock?

Astellas Pharma (ALPMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks | 1 year ago
Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?

Is Astellas Pharma (ALPMY) Outperforming Other Medical Stocks This Year?

Here is how Astellas Pharma Inc. (ALPMY) and AngioDynamics (ANGO) have performed compared to their sector so far this year.

Zacks | 1 year ago
Should Value Investors Buy Astellas Pharma (ALPMY) Stock?

Should Value Investors Buy Astellas Pharma (ALPMY) Stock?

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Zacks | 1 year ago
Astellas: Can The Gastric Cancer Approval Be The Inflection Point?

Astellas: Can The Gastric Cancer Approval Be The Inflection Point?

Astellas: Can The Gastric Cancer Approval Be The Inflection Point?

Seekingalpha | 1 year ago
FDA approves Astellas' gastric cancer therapy

FDA approves Astellas' gastric cancer therapy

The U.S. Food and Drug Administration approved Astellas' gastric cancer therapy, the health regulator's website showed on Friday.

Reuters | 1 year ago
Loading...
Load More